Citations

Mayo Clinic

Showing 10 of 108523 citations.

Myeloma Therapy for Monoclonal Gammopathy of Thrombotic Significance
Salmasi, Giselle, Murray, David , Padmanabhan, Anand , Padmanabhan, Anand , Salmasi, Giselle

New England Journal of Medicine | August 7, 2024 | Volume: 391 | Issue: 6 | Pages: 570-571

10.1056/nejmc2406453 | PMID 39115069 Get It

Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
Hoff, Fieke W. , Blum, William , Huang, Ying , Welkie, Rina Li , Swords, Ronan , Traer, Elie , Stein, Eytan M. , Lin, Tara L. , Patel, Prapti A. , Collins, Robert H. , Baer, Maria R. , Arellano, Martha , Odenike, Olatoyosi , Redner, Robert L. , Kovacsovics, Tibor , Deininger, Michael W. , Olin, Rebecca L. , Foran, James M. , Schiller, Gary J. , Curran, Emily , Koenig, Kristin L , Heerema, Nyla A. , Chen, Timothy L. , Martycz, Molly , Stefanos, Mona , Marcus, Sonja G., Rosenberg, Leonard, Burd, Amy , Yocum, Ashley O. , Borate, Uma , Byrd, John C. , Madanat, Yazan F. , Huang, Ying , Byrd, John C. , Duong, Vu H , Deininger, Michael , Zeidner, Joshua F , Smith, Catherine C , Koenig, Kristin L , Druker, Brian J , Mims, Alice S , Madanat, Yazan , Traer, Elie , Lin, Tara L , Byrd, John C , Archer, Kellie J. , Duong, Vu H. , Stock, Wendy , Zeidner, Joshua F. , Smith, Catherine C. , Marcus, Sonja G., Levine, Ross L.

Blood Advances | August 7, 2024 | Volume: 8 | Issue: 20 | Pages: 5297-5305

10.1182/bloodadvances.2024013685 | PMID 39110987 Get It

Abstract Although the 2022 European LeukemiaNet (ELN) acute myeloid leukemia (AML) risk classification reliably predicts outcomes in younger patients treated with intensive chemotherapy, it is unclear whether it applies to adults ≥60 years treated with lower-intensity treatment (LIT). We aimed to test the prognostic impact of ELN risk in patients with newly diagnosed (ND) AML aged ≥60 years given LIT and to further refine risk stratification for these patients. A total of 595 patients were included: 11% had favorable-, 11% intermediate-, and 78% had adverse-risk AML. ELN risk was prognostic for overall survival (OS) (P < .001) but did not stratify favorable- from intermediate-risk (P = .71). Within adverse-risk AML, the impact of additional molecular abnormalities was further evaluated. Multivariable analysis was performed on a training set (n = 316) and identified IDH2 mutation as an independent favorable prognostic factor, and KRAS, MLL2, and TP53 mutations as unfavorable (P < .05). A “mutation score” was calculated for each combination of these mutations, assigning adverse-risk patients to 2 risk groups: −1 to 0 points (“Beat-AML intermediate”) vs 1+ points (“Beat-AML adverse”). In the final refined risk classification, ELN favorable- and intermediate-risk were combined into a newly defined “Beat-AML favorable-risk” group, in addition to mutation scoring within the ELN adverse-risk group. This approach redefines risk for older patients with ND AML and proposes refined Beat-AML risk groups with improved discrimination for OS (2-year OS, 48% vs 33% vs 11%, respectively; P < .001), providing patients and providers additional information for treatment decision-making.
Accuracy and Completeness of Large Language Models About Antibody–Drug Conjugates and Associated Ocular Adverse Effects
Marshall, Rayna , Xu, Hannah , Mishra, Kapil , Edalat, Camellia , Kirupaharan, Nila , Dalvin, Lauren A. , Francis, Jasmine H. , Berkenstock, Meghan

Cornea | August 7, 2024 | Volume: 44 | Issue: 7 | Pages: 851-855

10.1097/ico.0000000000003664 | PMID 39110155 Get It

Purpose: The purpose of this study was to assess the accuracy and completeness of 3 large language models (LLMs) to generate information about antibody–drug conjugate (ADC)-associated ocular toxicities. Methods: There were 22 questions about ADCs, tisotumab vedotin, and mirvetuximab soravtansine that were developed and input into ChatGPT 4.0, Bard, and LLaMa. Answers were rated by 4 ocular toxicity experts using standardized 6-point Likert scales on accuracy and completeness. ANOVA tests were conducted for comparison between the 3 subgroups, followed by pairwise t-tests. Interrater variability was assessed with Fleiss kappa tests. Results: The mean accuracy score was 4.62 (SD 0.89) for ChatGPT, 4.77 (SD 0.90) for Bard, and 4.41 (SD 1.09) for LLaMA. Both ChatGPT (P = 0.03) and Bard (P = 0.003) scored significantly better for accuracy when compared with LLaMA. The mean completeness score was 4.43 (SD 0.91) for ChatGPT, 4.57 (SD 0.93) for Bard, and 4.42 (SD 0.99) for LLaMA. There were no significant differences in completeness scores between groups. Fleiss kappa assessment for interrater variability was good (0.74) for accuracy and fair (0.31) for completeness. Conclusions: All 3 LLMs had relatively high accuracy and completeness ratings, showing LLMs are able to provide sufficient answers for niche topics of ophthalmology. Our results indicate that ChatGPT and Bard may be slightly better at providing more accurate answers than LLaMA. As further research and treatment plans are developed for ADC-associated ocular toxicities, these LLMs should be reassessed to see if they provide complete and accurate answers that remain in line with current medical knowledge.
Neighborhood Socioeconomic Disadvantage Across the Life Course and Premature Mortality
Lawrence, Wayne R. , Kucharska‐Newton, Anna , George, Kristen M. , Lutsey, Pamela L. , Sullivan, Kevin , Carson, April P. , Carson, April P , Sullivan, Kevin J , Lutsey, Pamela L , Kucharska-Newton, Anna M , Lawrence, Wayne R , Magnani, Jared W. , Brewer, LaPrincess C. , Shiels, Meredith S. , Jenkins, Brittany Denise , Freedman, Neal D.

JAMA Network Open | August 7, 2024 | Volume: 7 | Issue: 8 | Pages: e2426243

10.1001/jamanetworkopen.2024.26243 | PMID 39110459 Get It

ImportanceThere are consistent data demonstrating that socioeconomic disadvantage is associated with risk of premature mortality, but research on the relationship between neighborhood socioeconomic factors and premature mortality is limited. Most studies evaluating the association between neighborhood socioeconomic status (SES) and mortality have used a single assessment of SES during middle to older adulthood, thereby not considering the contribution of early life neighborhood SES.ObjectiveTo investigate the association of life course neighborhood SES and premature mortality.Design, Setting, and ParticipantsThis cohort study included Black and White participants of the multicenter Atherosclerosis Risk in Communities Study, a multicenter study conducted in 4 US communities: Washington County, Maryland; Forsyth County, North Carolina; Jackson, Mississippi; and the northwestern suburbs of Minneapolis, Minnesota. Participants were followed up for a mean (SD) of 18.8 (5.7) years (1996-2020). Statistical analysis was performed from March 2023 through May 2024.ExposureParticipants’ residential addresses during childhood, young adulthood, and middle adulthood were linked with US Census–based socioeconomic indicators to create summary neighborhood SES scores for each of these life epochs. Neighborhood SES scores were categorized into distribution-based tertiles.Main Outcomes and MeasuresPremature death was defined as all-cause mortality occurring before age 75 years. Multivariable-adjusted Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs.ResultsAmong 12 610 study participants, the mean (SD) age at baseline was 62.6 (5.6) years; 3181 (25.2%) were Black and 9429 (74.8%) were White; and 7222 (57.3%) were women. The lowest, compared with the highest tertile, of neighborhood SES score in middle adulthood was associated with higher risk of premature mortality (HR, 1.28; 95% CI, 1.07-1.54). Similar associations were observed for neighborhood SES in young adulthood among women (HR, 1.25; 95% CI, 1.00-1.56) and neighborhood SES in childhood among White participants (HR, 1.25; 95% CI, 1.01-1.56). Participants whose neighborhood SES remained low from young to middle adulthood had an increased premature mortality risk compared with those whose neighborhood SES remained high (HR, 1.25; 95% CI, 1.05-1.49).Conclusions and RelevanceIn this study, low neighborhood SES was associated with premature mortality. The risk of premature mortality was greatest among individuals experiencing persistently low neighborhood SES from young to middle adulthood. Place-based interventions that target neighborhood social determinants of health should be designed from a life course perspective that accounts for early-life socioeconomic inequality.
A Vaping Cessation Text Message Program for Adolescent E-Cigarette Users
Cha, Sarah , Funsten, Anna L., Edwards, Giselle , Graham, Amanda L. , Jacobs, Megan A , Amato, Michael S. , Papandonatos, George D.

JAMA | August 7, 2024 | Volume: 332 | Issue: 9 | Pages: 713

10.1001/jama.2024.11057 | PMID 39110436 Get It

ImportanceE-cigarettes are the most commonly used tobacco product among adolescents. Despite known harms of nicotine exposure among teens, there are no empirically tested vaping cessation interventions.ObjectiveTo compare the effectiveness of a text message program for nicotine vaping cessation among adolescents with assessment-only control.Design, Setting, and ParticipantsA parallel, 2-group, double-blind, individually randomized clinical trial with follow-ups at 1 and 7 months after randomization was conducted from October 1, 2021, to October 18, 2023. Participants were recruited via social media ads; the intervention was delivered via text message; and assessments were completed online or by telephone. Eligible individuals were US residents aged 13 to 17 years who reported past 30-day e-cigarette use, were interested in quitting within 30 days, and owned a mobile phone with an active text message plan. To optimize study retention, all participants received monthly assessments via text message about e-cigarette use.InterventionsAssessment-only controls (n = 744) received only study retention text messages. Intervention participants (n = 759) also received an automated, interactive text message program for vaping cessation that delivers cognitive and behavioral coping skills training and social support.Main Outcomes and MeasuresThe primary outcome was self-reported 30-day point-prevalence abstinence from vaping at 7 months analyzed as intention-to-treat, with missingness coded as vaping.ResultsAmong n = 1503 adolescents randomized, average age was 16.4 (SD, 0.8) years. The sample was 50.6% female, 42.1% male, and 7.4% nonbinary/other; 10.2% Black/African American, 62.6% White, 18.5% multiracial, and 8.7% another race; 16.2% Hispanic; 42.5% sexual minority; and 76.2% vaped within 30 minutes of waking. The 7-month follow-up rate was 70.8%. Point-prevalence abstinence rates were 37.8% (95% CI, 34.4%-41.3%) among intervention participants and 28.0% (95% CI, 24.9%-31.3%) among control participants (relative risk, 1.35 [95% CI, 1.17-1.57]; P < .001). No baseline variables moderated the treatment-outcome relationship. There was no evidence that adolescents who quit vaping transitioned to combustible tobacco products.Conclusions and RelevanceA tailored, interactive text message intervention increased self-reported vaping cessation rates among adolescents recruited via social media channels.Trial RegistrationClinicalTrials.gov Identifier: NCT04919590
Outcomes of surgical resection and vagus nerve stimulation in patients with medically refractory epilepsy and glutamic acid decarboxylase 65 antibody positivity
Zhao-Fleming, Hannah , Dubey, Divyanshu , Smith, Kelsey M. , Zhao-Fleming, Hannah H, Dubey, Divyanshu , Smith, Kelsey M , Guo, Yong , Britton, Jeffrey W.

Epilepsia | August 7, 2024 | Volume: 65 | Issue: 10 | Pages: No page available

10.1111/epi.18086 | PMID 39110151 Get It

AbstractEpilepsy associated with high‐titer glutamic acid decarboxylase 65 (GAD65) IgG is often refractory to immunotherapies and antiseizure medication. This study sought to determine the efficacy of vagus nerve stimulation (VNS) and surgical resection in patients with drug‐resistant epilepsy associated with GAD65‐IgG. We retrospectively identified 15 patients with drug‐resistant epilepsy and high serum GAD65 antibody titers (>20 nmol·L−1) who underwent VNS implantation (n = 6), surgical resection (n = 7), or both (n = 2). A responder to VNS was defined as someone with a ≥50% reduction in seizure frequency, and a favorable surgical outcome was defined as Engel I–II. Of the eight patients who underwent VNS implantation, three (37.5%) were initially responders, but this was not sustained in two. Of the nine patients who underwent surgical resection, three (33.3%) had a favorable outcome; however, only one patient was seizure‐free at last follow‐up. Pathology was available in six patients, and only one had evidence of inflammation; this patient had seizure onset 1 year prior to surgery. Favorable seizure outcome correlated with older age at time of resective surgery, with a trend favoring later age of seizure onset. Taken together, surgical resection and VNS implantation may have limited efficacy in this patient population but can be considered in carefully selected cases.
Cell-specific cross-talk proteomics reveals cathepsin B signaling as a driver of glioblastoma malignancy near the subventricular zone
Norton, Emily S. , Whaley, Lauren , Jones, Vanessa K. , Brooks, Mieu, Russo, Marissa , Morderer, Dmytro , Jessen, Erik , Carrano, Anna , Asmann, Yan W. , Lam, TuKiet T. , Chaichana, Kaisorn L. , Anastasiadis, Panos Z. , Quiñones‐Hinojosa, Alfredo , Guerrero‐Cazares, Hugo , Whaley, Lauren A , Brooks, Mieu M, Russo, Marissa N., Schiapparelli, Paula , Zarco, Natanael , Carrano, Anna , Rossoll, Wilfried , Asmann, Yan W , Lam, TuKiet T , Anastasiadis, P Z , Guerrero-Cazares, Hugo , Ramos‐Fresnedo, Andres , Zarco, Natanael

Science Advances | August 7, 2024 | Volume: 10 | Issue: 32 | Pages: No page available

10.1126/sciadv.adn1607 | PMID 39110807 Get It

Glioblastoma (GBM) is the most prevalent and aggressive malignant primary brain tumor. GBM proximal to the lateral ventricles (LVs) is more aggressive, potentially because of subventricular zone contact. Despite this, cross-talk between GBM and neural stem/progenitor cells (NSC/NPCs) is not well understood. Using cell-specific proteomics, we show that LV-proximal GBM prevents neuronal maturation of NSCs through induction of senescence. In addition, GBM brain tumor–initiating cells (BTICs) increase expression of cathepsin B (CTSB) upon interaction with NPCs. Lentiviral knockdown and recombinant protein experiments reveal that both cell-intrinsic and soluble CTSB promote malignancy-associated phenotypes in BTICs. Soluble CTSB stalls neuronal maturation in NPCs while promoting senescence, providing a link between LV-tumor proximity and neurogenesis disruption. Last, we show LV-proximal CTSB up-regulation in patients, showing the relevance of this cross-talk in human GBM biology. These results demonstrate the value of proteomic analysis in tumor microenvironment research and provide direction for new therapeutic strategies in GBM.
Response to Letter by Zagardo, et al.
Grigsby-Rocca, Giovanna , Bermudez, Camilo , White, Jessica D. , Neth, Bryan J. , Uhm, Joon H. , Mustafa, Rafid , Neth, Byran J. , Mustafa, Rafid , White, Jessica D.

The Neurohospitalist | August 7, 2024 | Volume: 14 | Issue: 4 | Pages: 471-471

10.1177/19418744241273115 | PMID 39308472 Get It

Predicted Net Effects of Drug-Gene Interactions on Levels of Tetrahydrocannabinol and Cannabidiol
Huang, Linda , Yadav, Siddhant, Singla, Abhinav , Vincent, Ann, Wright, Jessica , Katamesh, Basant E.

No container title available | August 7, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4731545/v1 Get It

Abstract Background: Circulating levels of THC and CBD may be altered when administered with medications that strongly or moderately inhibit or induce CYP450 enzymes responsible for metabolizing both substances. THC and CBD levels can also theoretically be altered in individuals who carry germline genetic variants or atypical phenotypes of CYP450 enzymes. In individuals where drug and gene interactions occur together, there could be a heightened impact on the circulating levels of THC and CBD. Materials and Methods: We conducted a retrospective chart review using a database of participants who previously completed pharmacogenomic testing and reported oral cannabis use in a medical encounter. Two pharmacogenomic-trained pharmacists reviewed medications and atypical variants in each participant to characterize the predicted effect of cannabis-drug, cannabis-gene, and cannabis-drug-gene interactions on circulating levels of THC and CBD. Results: Oral cannabis use was confirmed in 71 participants, with an average age of 68.5 years and primarily White women. Regarding THC metabolism, drug-only interactions were noted in 1 participant; both drug and gene interactions were noted in 4 participants; single- or combination-gene-only interactions were noted in 38 participants; and 28 participants had no interactions. Concerning CBD metabolism, drug-only interactions were noted in 4 participants; both drug and gene interactions were noted in 4 participants; single- or combination-gene-only interactions were noted in 36 participants; and 27 participants had no interactions. Conclusion: This study is the first, to our knowledge, to conceptualize the potential impact of drugs and atypical phenotypes on altering circulating levels of THC and CBD in a clinical sample. The absence of published clinical outcomes in this field renders it challenging to estimate clinical significance of these findings. Until such data become available, leveraging the theoretical insights into drug interactions and atypical cannabis metabolism described in our study may serve as a tool to guide clinical care.
Radiotherapy and Systemic Treatment for Leptomeningeal Disease
Frechette, K.M., Breen, William G. , Brown, Paul D. , Sener, Uğur , Webb, Lauren M. , Mahajan, Anita , Lehrer, Eric J. , Frechette, Kelsey M , Sener, Ugur , Webb, Lauren Michelle , Routman, David M. , Laack, Nadia N.

Biomedicines | August 7, 2024 | Volume: 12 | Issue: 8 | Pages: 1792

10.3390/biomedicines12081792 | PMID 39200256 Get It

Leptomeningeal disease (LMD) is a devastating sequelae of metastatic spread that affects approximately 5% of cancer patients. The incidence of LMD is increasing due to advancements in systemic therapy and enhanced detection methods. The purpose of this review is to provide a detailed overview of the evidence in the detection, prognostication, and treatment of LMD. A comprehensive literature search of PUBMED was conducted to identify articles reporting on LMD including existing data and ongoing clinical trials. We found a wide array of treatment options available for LMD including chemotherapy, targeted agents, and immunotherapy as well as several choices for radiotherapy including whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), and craniospinal irradiation (CSI). Despite treatment, the prognosis for patients with LMD is dismal, typically 2–4 months on average. Novel therapies and combination approaches are actively under investigation with the aim of improving outcomes and quality of life for patients with LMD. Recent prospective data on the use of proton CSI for patients with LMD have demonstrated its potential survival benefit with follow-up investigations underway. There is a need for validated metrics to predict prognosis and improve patient selection for patients with LMD in order to optimize treatment approaches.